Sarcoma, Synovial clinical trials

The registry lists 101 studies for Sarcoma, Synovial across more than 10 countries. 28 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-04.

Studies

Recruiting first, then most recently updated. Showing 50 of 101 — search for more.

• First-in-Human Trial of DS-2243a in Participants With Advanced Solid TumorsRecruitingNCT06644755Phase 15 countries
• Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaRecruitingNCT05711615Phase 11 country
• A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid MalignanciesRecruitingNCT07613723Phase 11 country
• N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular TherapyRecruitingNCT07261657Early Phase 11 country
• Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-celAvailableNCT066175721 country
• SPEARHEAD-3 Pediatric StudyRecruitingNCT05642455Phase 1/21 country
• Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare CancersNot yet recruitingNCT07686367Phase 2
• NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)RecruitingNCT06239272Phase 1/21 country
• Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1RecruitingNCT06083883Phase 11 country
• TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid TumorsNot yet recruitingNCT07713732Phase 11 country
• AOH1996 for the Treatment of Refractory Solid TumorsRecruitingNCT05227326Phase 11 country
• Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsRecruitingNCT06625190Phase 1/21 country
• XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue SarcomaRecruitingNCT06571734Phase 21 country
• Synovial Sarcoma Registry / Biospecimen RepositoryRecruitingNCT059103071 country
• Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).RecruitingNCT06607692Phase 1/21 country
• START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of CancerRecruitingNCT05492682Phase 12 countries
• Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)RecruitingNCT06094101Phase 1/21 country
• Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)RecruitingNCT03016819Phase 35 countries
• Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial SarcomaRecruitingNCT07174427Phase 31 country
• Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue SarcomaRecruitingNCT07169344Phase 21 country
• Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.RecruitingNCT07173972Phase 21 country
• HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced SarcomaRecruitingNCT04995003Phase 11 country
• ACTengine® IMA203 Combined With mRNA-4203RecruitingNCT06946225Phase 11 country
• Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersRecruitingNCT05296564Phase 1/21 country
• MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue SarcomaRecruitingNCT06277154Phase 21 country
• Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced SarcomasRecruitingNCT07066982Phase 1/21 country
• Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell TumorRecruitingNCT06456359Phase 21 country
• EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial SarcomaNot yet recruitingNCT06748872Phase 11 country
• Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaActive, not recruitingNCT04044768Phase 25 countries
• Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid TumorsActive, not recruitingNCT03967223Phase 27 countries
• Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1Active, not recruitingNCT02650986Phase 1/21 country
• Tazemetostat Expanded Access Program for Adults With Solid TumorsNo longer availableNCT03874455
• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryCompletedNCT02180867Phase 2/33 countries
• APX005M and Doxorubicin in Advanced SarcomaCompletedNCT03719430Phase 21 country
• MAGE-A4ᶜ¹º³²T for Multi-TumorActive, not recruitingNCT03132922Phase 12 countries
• B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsActive, not recruitingNCT04483778Phase 11 country
• Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasActive, not recruitingNCT03478462Phase 13 countries
• Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaActive, not recruitingNCT04420975Phase 11 country
• Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma PatientsCompletedNCT04008238Not applicable1 country
• Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid TumorsActive, not recruitingNCT02869217Phase 11 country
• EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsActive, not recruitingNCT03618381Phase 11 country
• A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical StudyCompletedNCT02875548Phase 1/27 countries
• A Study of Tazemetostat in Adult Participants With Soft Tissue SarcomaCompletedNCT02601950Phase 29 countries
• FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss TumorsTerminatedNCT04965753Phase 14 countries
• Effects of Itraconazole and Rifampin on the Blood Tazemetostat LevelsCompletedNCT04537715Phase 12 countries
• The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT040284791 country
• A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null TumorsTerminatedNCT05355753Phase 11 country
• Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial SarcomaCompletedNCT03250325Phase 1/21 country
• Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung CancerTerminatedNCT06048705Phase 16 countries
• Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell LiposarcomaTerminatedNCT05943990Phase 16 countries